DRUGS WITH SENOLYTIC ACTIVITY: PROSPECTS AND POSSIBLE LIMITATIONS

Abstract

The search and testing of drugs with senolytic activity is one of the new directions in gerontology. The number of “senescent” cells that increases with age contributes to the development of age-related diseases and chronic non-infectious inflammation. Removing “senescent” cells or suppressing their influence on surrounding tissues seems a logical step to improve the quality of life and, possibly, prolong lifespan. However, drugs that have senolytic and senomorphic activity in model systems cause the development of a number of side effects in clinical trials. In this review, we consider the main advances in the field of senotherapy, the prospects for the use of senotherapy drugs, and the limitations that researchers and clinicians may encounter.